Rosa, Arianna Carolina and Nardini, Patrizia and Sgambellone, Silvia and Gurrieri, Maura and Spampinato, Simona Federica and Dell’Accio, Alfonso and Chazot, Paul L and Obara, Ilona and Liu, Wai L and Pini, Alessandro (2022) 'CNS-Sparing Histamine H3 Receptor Antagonist as a Candidate to Prevent the Diabetes-Associated Gastrointestinal Symptoms.', Biomolecules, 12 (2).
Among the histamine receptors, growing evidence points to the histamine H3 receptor as a pharmacological candidate to counteract the autonomic neuropathy associated with diabetes. The study aimed to evaluate the effect of PF00868087 (also known as ZPL-868), a CNS-sparing histamine H3 receptor antagonist, on the autonomic neuropathy of the intestinal tract associated with diabetes. Diabetes was induced in male BALB/c mice by a single high dose of streptozotocin (150 mg/kg). Colorectal specimens from control and diabetic mice, randomized to vehicle or PF0086087 (10, 30, 100 mg/kg/day by oral gavage for 14 days), were processed for morphological and immunohistochemical analysis. A significant overproduction of mucus in the intestinal mucosa of diabetic mice compared to the controls was observed. PF0086087 at the highest dose prevented mucin overproduction. The immunohistochemistry analysis demonstrated that diabetes causes a decrease in the inhibitory component of enteric motility, measured as the percentage of neuronal nitric oxide synthase-positive neurons (p < 0.05) and a parallel increase in the excitatory component evaluated as substance P-positive fibres (p < 0.01). PF0086087 dose-dependently prevented these pathophysiological events. In conclusion, PF0086087 may be an essential tool in preventing nitrergic dysfunction in the myenteric plexus of the distal colon and diabetes-induced gastrointestinal complications.
|Full text:||(VoR) Version of Record|
Available under License - Creative Commons Attribution 4.0.
Download PDF (3409Kb)
|Publisher Web site:||https://doi.org/10.3390/biom12020184|
|Publisher statement:||This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).|
|Date accepted:||20 January 2022|
|Date deposited:||15 March 2022|
|Date of first online publication:||22 January 2022|
|Date first made open access:||15 March 2022|
Save or Share this output
|Look up in GoogleScholar|